Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data

Introduction and Objectives: Atrial fibrillation (AF) is the most common form of arrhythmia worldwide and a significant health burden. Edoxaban, a recent novel oral anticoagulant (NOAC), is being investigated in the European real-world ETNA-AF study of patients with non-valvular atrial fibrillation (NVAF). The aim of this study was to characterize the Iberian edoxaban-treated cohort of ETNA-AF at baseline and to compare it with previously retrieved Portuguese data. Methods: Patients with NVAF treated with edoxaban and followed in Portuguese and Spanish centers were consecutively enrolled between June 2017 and January 2018. Only patients with a previous clinical decision to receive edoxaban were included. Patients’ baseline demographic and clinical parameters, medical history, and AF-related characteristics were retrieved. Results: A total of 892 NVAF patients, with a mean age of 73.9 years, were included, 75.3% of whom received high-dose (60 mg) and 24.7% low-dose (30 mg) edoxaban. Most patients (55.9%) were male. Of the patients receiving 30 mg and 60 mg edoxaban, 55.9% and 37.9%, respectively, had an estimated CHA2DS2-VASc score ≥4. Previous bleeding event rates were low, with a predominance of clinically relevant non-major bleeding (1.9%). Most patients (47.5%) with NVAF had paroxysmal AF, followed by 26.4% with permanent AF. Median overall CHA2DS2-VASc score was 3.0 and median HAS-BLED score was 2.0. Previous treatments mostly included vitamin K antagonists (35.7%). A considerably higher proportion of patients on low-dose edoxaban required dose adjustments (71.4% vs. 8.6%). Overall adherence to label dosing recommendations was 86.5%. Conclusions: This study provides valuable data on disease and patient profiles and will provide valuable insights into disease management and progression, as well as the safety, effectiveness, and patterns of cardiovascular events associated with edoxaban. Resumo: Introdução e objetivos: A fibrilhação auricular (FA) é a arritmia mais comum globalmente e associa-se a um substancial ónus de saúde. O novo anticoagulante oral (NOAC) edoxabano está a ser investigado no estudo europeu de vida real ETNA-AF em doentes com fibrilhação auricular não valvular (FANV). O objetivo deste estudo é caracterizar a coorte ibérica do ETNA-AF na base de dados e compará-la com dados portugueses prévios. Métodos: Doentes com FANV tratados com edoxabano e seguidos em centros portugueses e espanhóis foram consecutivamente incluídos no estudo entre junho de 2017 e janeiro de 2018. Apenas doentes com indicação prévia para receber edoxabano foram incluídos e os seus dados clínicos e demográficos, história clínica e características relacionadas com a FA foram registados. Resultados: Fora, incluídos 892 doentes com FANV, com média de 73,9 anos, 75,3% dos quais receberam a dose elevada (60 mg) e 24,7% a dose reduzida (30 mg) de edoxabano. A maioria dos doentes (55,9%) era do sexo masculino. Dos doentes que receberam 30 mg e 60 mg de edoxabano, 55,9% e 37,9%, respetivamente, tinham CHA2DS2-VASc estimado ≥ 4. As taxas de eventos hemorrágicos prévios foram baixas, com predominância de hemorragia não major clinicamente relevante (1,9%). A maioria (47,5%) dos doentes com FANV tinha FA paroxística, seguidos de 26,4% com FA permanente. A mediana de CHA2DS2-VASc global foi 3,0 e a mediana de HAS-BLED, 2,0. Os tratamentos prévios incluíram sobretudo VKAs (35,7%). Uma proporção consideravelmente maior de doentes a receber dose reduzida de edoxabano necessitou de ajustes de dose (71,4% versus 8,6%). A adesão global às recomendações de dose foi de 86,5%. Conclusões: Este estudo fornece dados importantes sobre a doença e o perfil dos doentes e possibilitará considerações futuras acerca da gestão e progressão da doença, bem como de segurança, efetividade e padrões de eventos cardiovasculares associados a edoxabano. Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Pedro Monteiro [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch ; Portugiesisch

Erschienen:	2020

Schlagwörter:	Fibrilhação auricular Edoxabano Baseline Vida real

Übergeordnetes Werk:	In: Revista Portuguesa de Cardiologia - Elsevier, 2020, 39(2020), 11, Seite 651-662
Übergeordnetes Werk:	volume:39 ; year:2020 ; number:11 ; pages:651-662

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1016/j.repc.2020.09.003

Katalog-ID:	DOAJ044087381

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ044087381
003	DE-627
005	20230501190657.0
007	cr uuu---uuuuu
008	230227s2020 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.repc.2020.09.003 \|2 doi
035			\|a (DE-627)DOAJ044087381
035			\|a (DE-599)DOAJ6a1eeab3a2fa490c9eaf0ab85f29cf75
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng \|a por
050		0	\|a RC666-701
100	0		\|a Pedro Monteiro \|e verfasserin \|4 aut
245	1	0	\|a Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Introduction and Objectives: Atrial fibrillation (AF) is the most common form of arrhythmia worldwide and a significant health burden. Edoxaban, a recent novel oral anticoagulant (NOAC), is being investigated in the European real-world ETNA-AF study of patients with non-valvular atrial fibrillation (NVAF). The aim of this study was to characterize the Iberian edoxaban-treated cohort of ETNA-AF at baseline and to compare it with previously retrieved Portuguese data. Methods: Patients with NVAF treated with edoxaban and followed in Portuguese and Spanish centers were consecutively enrolled between June 2017 and January 2018. Only patients with a previous clinical decision to receive edoxaban were included. Patients’ baseline demographic and clinical parameters, medical history, and AF-related characteristics were retrieved. Results: A total of 892 NVAF patients, with a mean age of 73.9 years, were included, 75.3% of whom received high-dose (60 mg) and 24.7% low-dose (30 mg) edoxaban. Most patients (55.9%) were male. Of the patients receiving 30 mg and 60 mg edoxaban, 55.9% and 37.9%, respectively, had an estimated CHA2DS2-VASc score ≥4. Previous bleeding event rates were low, with a predominance of clinically relevant non-major bleeding (1.9%). Most patients (47.5%) with NVAF had paroxysmal AF, followed by 26.4% with permanent AF. Median overall CHA2DS2-VASc score was 3.0 and median HAS-BLED score was 2.0. Previous treatments mostly included vitamin K antagonists (35.7%). A considerably higher proportion of patients on low-dose edoxaban required dose adjustments (71.4% vs. 8.6%). Overall adherence to label dosing recommendations was 86.5%. Conclusions: This study provides valuable data on disease and patient profiles and will provide valuable insights into disease management and progression, as well as the safety, effectiveness, and patterns of cardiovascular events associated with edoxaban. Resumo: Introdução e objetivos: A fibrilhação auricular (FA) é a arritmia mais comum globalmente e associa-se a um substancial ónus de saúde. O novo anticoagulante oral (NOAC) edoxabano está a ser investigado no estudo europeu de vida real ETNA-AF em doentes com fibrilhação auricular não valvular (FANV). O objetivo deste estudo é caracterizar a coorte ibérica do ETNA-AF na base de dados e compará-la com dados portugueses prévios. Métodos: Doentes com FANV tratados com edoxabano e seguidos em centros portugueses e espanhóis foram consecutivamente incluídos no estudo entre junho de 2017 e janeiro de 2018. Apenas doentes com indicação prévia para receber edoxabano foram incluídos e os seus dados clínicos e demográficos, história clínica e características relacionadas com a FA foram registados. Resultados: Fora, incluídos 892 doentes com FANV, com média de 73,9 anos, 75,3% dos quais receberam a dose elevada (60 mg) e 24,7% a dose reduzida (30 mg) de edoxabano. A maioria dos doentes (55,9%) era do sexo masculino. Dos doentes que receberam 30 mg e 60 mg de edoxabano, 55,9% e 37,9%, respetivamente, tinham CHA2DS2-VASc estimado ≥ 4. As taxas de eventos hemorrágicos prévios foram baixas, com predominância de hemorragia não major clinicamente relevante (1,9%). A maioria (47,5%) dos doentes com FANV tinha FA paroxística, seguidos de 26,4% com FA permanente. A mediana de CHA2DS2-VASc global foi 3,0 e a mediana de HAS-BLED, 2,0. Os tratamentos prévios incluíram sobretudo VKAs (35,7%). Uma proporção consideravelmente maior de doentes a receber dose reduzida de edoxabano necessitou de ajustes de dose (71,4% versus 8,6%). A adesão global às recomendações de dose foi de 86,5%. Conclusões: Este estudo fornece dados importantes sobre a doença e o perfil dos doentes e possibilitará considerações futuras acerca da gestão e progressão da doença, bem como de segurança, efetividade e padrões de eventos cardiovasculares associados a edoxabano.
650		4	\|a Fibrilhação auricular
650		4	\|a Edoxabano
650		4	\|a Baseline
650		4	\|a Vida real
653		0	\|a Diseases of the circulatory (Cardiovascular) system
773	0	8	\|i In \|t Revista Portuguesa de Cardiologia \|d Elsevier, 2020 \|g 39(2020), 11, Seite 651-662 \|w (DE-627)642886164 \|w (DE-600)2586869-X \|x 21742030 \|7 nnns
773	1	8	\|g volume:39 \|g year:2020 \|g number:11 \|g pages:651-662
856	4	0	\|u https://doi.org/10.1016/j.repc.2020.09.003 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/6a1eeab3a2fa490c9eaf0ab85f29cf75 \|z kostenfrei
856	4	0	\|u http://www.sciencedirect.com/science/article/pii/S0870255120304066 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/0870-2551 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 39 \|j 2020 \|e 11 \|h 651-662

Indexfelder

author_variant	p m pm
matchkey_str	article:21742030:2020----::dxbnramniruielnclrcienainsihovluaarafbil
hierarchy_sort_str	2020
callnumber-subject-code	RC
publishDate	2020
allfields	10.1016/j.repc.2020.09.003 doi (DE-627)DOAJ044087381 (DE-599)DOAJ6a1eeab3a2fa490c9eaf0ab85f29cf75 DE-627 ger DE-627 rakwb eng por RC666-701 Pedro Monteiro verfasserin aut Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction and Objectives: Atrial fibrillation (AF) is the most common form of arrhythmia worldwide and a significant health burden. Edoxaban, a recent novel oral anticoagulant (NOAC), is being investigated in the European real-world ETNA-AF study of patients with non-valvular atrial fibrillation (NVAF). The aim of this study was to characterize the Iberian edoxaban-treated cohort of ETNA-AF at baseline and to compare it with previously retrieved Portuguese data. Methods: Patients with NVAF treated with edoxaban and followed in Portuguese and Spanish centers were consecutively enrolled between June 2017 and January 2018. Only patients with a previous clinical decision to receive edoxaban were included. Patients’ baseline demographic and clinical parameters, medical history, and AF-related characteristics were retrieved. Results: A total of 892 NVAF patients, with a mean age of 73.9 years, were included, 75.3% of whom received high-dose (60 mg) and 24.7% low-dose (30 mg) edoxaban. Most patients (55.9%) were male. Of the patients receiving 30 mg and 60 mg edoxaban, 55.9% and 37.9%, respectively, had an estimated CHA2DS2-VASc score ≥4. Previous bleeding event rates were low, with a predominance of clinically relevant non-major bleeding (1.9%). Most patients (47.5%) with NVAF had paroxysmal AF, followed by 26.4% with permanent AF. Median overall CHA2DS2-VASc score was 3.0 and median HAS-BLED score was 2.0. Previous treatments mostly included vitamin K antagonists (35.7%). A considerably higher proportion of patients on low-dose edoxaban required dose adjustments (71.4% vs. 8.6%). Overall adherence to label dosing recommendations was 86.5%. Conclusions: This study provides valuable data on disease and patient profiles and will provide valuable insights into disease management and progression, as well as the safety, effectiveness, and patterns of cardiovascular events associated with edoxaban. Resumo: Introdução e objetivos: A fibrilhação auricular (FA) é a arritmia mais comum globalmente e associa-se a um substancial ónus de saúde. O novo anticoagulante oral (NOAC) edoxabano está a ser investigado no estudo europeu de vida real ETNA-AF em doentes com fibrilhação auricular não valvular (FANV). O objetivo deste estudo é caracterizar a coorte ibérica do ETNA-AF na base de dados e compará-la com dados portugueses prévios. Métodos: Doentes com FANV tratados com edoxabano e seguidos em centros portugueses e espanhóis foram consecutivamente incluídos no estudo entre junho de 2017 e janeiro de 2018. Apenas doentes com indicação prévia para receber edoxabano foram incluídos e os seus dados clínicos e demográficos, história clínica e características relacionadas com a FA foram registados. Resultados: Fora, incluídos 892 doentes com FANV, com média de 73,9 anos, 75,3% dos quais receberam a dose elevada (60 mg) e 24,7% a dose reduzida (30 mg) de edoxabano. A maioria dos doentes (55,9%) era do sexo masculino. Dos doentes que receberam 30 mg e 60 mg de edoxabano, 55,9% e 37,9%, respetivamente, tinham CHA2DS2-VASc estimado ≥ 4. As taxas de eventos hemorrágicos prévios foram baixas, com predominância de hemorragia não major clinicamente relevante (1,9%). A maioria (47,5%) dos doentes com FANV tinha FA paroxística, seguidos de 26,4% com FA permanente. A mediana de CHA2DS2-VASc global foi 3,0 e a mediana de HAS-BLED, 2,0. Os tratamentos prévios incluíram sobretudo VKAs (35,7%). Uma proporção consideravelmente maior de doentes a receber dose reduzida de edoxabano necessitou de ajustes de dose (71,4% versus 8,6%). A adesão global às recomendações de dose foi de 86,5%. Conclusões: Este estudo fornece dados importantes sobre a doença e o perfil dos doentes e possibilitará considerações futuras acerca da gestão e progressão da doença, bem como de segurança, efetividade e padrões de eventos cardiovasculares associados a edoxabano. Fibrilhação auricular Edoxabano Baseline Vida real Diseases of the circulatory (Cardiovascular) system In Revista Portuguesa de Cardiologia Elsevier, 2020 39(2020), 11, Seite 651-662 (DE-627)642886164 (DE-600)2586869-X 21742030 nnns volume:39 year:2020 number:11 pages:651-662 https://doi.org/10.1016/j.repc.2020.09.003 kostenfrei https://doaj.org/article/6a1eeab3a2fa490c9eaf0ab85f29cf75 kostenfrei http://www.sciencedirect.com/science/article/pii/S0870255120304066 kostenfrei https://doaj.org/toc/0870-2551 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 39 2020 11 651-662
spelling	10.1016/j.repc.2020.09.003 doi (DE-627)DOAJ044087381 (DE-599)DOAJ6a1eeab3a2fa490c9eaf0ab85f29cf75 DE-627 ger DE-627 rakwb eng por RC666-701 Pedro Monteiro verfasserin aut Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction and Objectives: Atrial fibrillation (AF) is the most common form of arrhythmia worldwide and a significant health burden. Edoxaban, a recent novel oral anticoagulant (NOAC), is being investigated in the European real-world ETNA-AF study of patients with non-valvular atrial fibrillation (NVAF). The aim of this study was to characterize the Iberian edoxaban-treated cohort of ETNA-AF at baseline and to compare it with previously retrieved Portuguese data. Methods: Patients with NVAF treated with edoxaban and followed in Portuguese and Spanish centers were consecutively enrolled between June 2017 and January 2018. Only patients with a previous clinical decision to receive edoxaban were included. Patients’ baseline demographic and clinical parameters, medical history, and AF-related characteristics were retrieved. Results: A total of 892 NVAF patients, with a mean age of 73.9 years, were included, 75.3% of whom received high-dose (60 mg) and 24.7% low-dose (30 mg) edoxaban. Most patients (55.9%) were male. Of the patients receiving 30 mg and 60 mg edoxaban, 55.9% and 37.9%, respectively, had an estimated CHA2DS2-VASc score ≥4. Previous bleeding event rates were low, with a predominance of clinically relevant non-major bleeding (1.9%). Most patients (47.5%) with NVAF had paroxysmal AF, followed by 26.4% with permanent AF. Median overall CHA2DS2-VASc score was 3.0 and median HAS-BLED score was 2.0. Previous treatments mostly included vitamin K antagonists (35.7%). A considerably higher proportion of patients on low-dose edoxaban required dose adjustments (71.4% vs. 8.6%). Overall adherence to label dosing recommendations was 86.5%. Conclusions: This study provides valuable data on disease and patient profiles and will provide valuable insights into disease management and progression, as well as the safety, effectiveness, and patterns of cardiovascular events associated with edoxaban. Resumo: Introdução e objetivos: A fibrilhação auricular (FA) é a arritmia mais comum globalmente e associa-se a um substancial ónus de saúde. O novo anticoagulante oral (NOAC) edoxabano está a ser investigado no estudo europeu de vida real ETNA-AF em doentes com fibrilhação auricular não valvular (FANV). O objetivo deste estudo é caracterizar a coorte ibérica do ETNA-AF na base de dados e compará-la com dados portugueses prévios. Métodos: Doentes com FANV tratados com edoxabano e seguidos em centros portugueses e espanhóis foram consecutivamente incluídos no estudo entre junho de 2017 e janeiro de 2018. Apenas doentes com indicação prévia para receber edoxabano foram incluídos e os seus dados clínicos e demográficos, história clínica e características relacionadas com a FA foram registados. Resultados: Fora, incluídos 892 doentes com FANV, com média de 73,9 anos, 75,3% dos quais receberam a dose elevada (60 mg) e 24,7% a dose reduzida (30 mg) de edoxabano. A maioria dos doentes (55,9%) era do sexo masculino. Dos doentes que receberam 30 mg e 60 mg de edoxabano, 55,9% e 37,9%, respetivamente, tinham CHA2DS2-VASc estimado ≥ 4. As taxas de eventos hemorrágicos prévios foram baixas, com predominância de hemorragia não major clinicamente relevante (1,9%). A maioria (47,5%) dos doentes com FANV tinha FA paroxística, seguidos de 26,4% com FA permanente. A mediana de CHA2DS2-VASc global foi 3,0 e a mediana de HAS-BLED, 2,0. Os tratamentos prévios incluíram sobretudo VKAs (35,7%). Uma proporção consideravelmente maior de doentes a receber dose reduzida de edoxabano necessitou de ajustes de dose (71,4% versus 8,6%). A adesão global às recomendações de dose foi de 86,5%. Conclusões: Este estudo fornece dados importantes sobre a doença e o perfil dos doentes e possibilitará considerações futuras acerca da gestão e progressão da doença, bem como de segurança, efetividade e padrões de eventos cardiovasculares associados a edoxabano. Fibrilhação auricular Edoxabano Baseline Vida real Diseases of the circulatory (Cardiovascular) system In Revista Portuguesa de Cardiologia Elsevier, 2020 39(2020), 11, Seite 651-662 (DE-627)642886164 (DE-600)2586869-X 21742030 nnns volume:39 year:2020 number:11 pages:651-662 https://doi.org/10.1016/j.repc.2020.09.003 kostenfrei https://doaj.org/article/6a1eeab3a2fa490c9eaf0ab85f29cf75 kostenfrei http://www.sciencedirect.com/science/article/pii/S0870255120304066 kostenfrei https://doaj.org/toc/0870-2551 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 39 2020 11 651-662
allfields_unstemmed	10.1016/j.repc.2020.09.003 doi (DE-627)DOAJ044087381 (DE-599)DOAJ6a1eeab3a2fa490c9eaf0ab85f29cf75 DE-627 ger DE-627 rakwb eng por RC666-701 Pedro Monteiro verfasserin aut Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction and Objectives: Atrial fibrillation (AF) is the most common form of arrhythmia worldwide and a significant health burden. Edoxaban, a recent novel oral anticoagulant (NOAC), is being investigated in the European real-world ETNA-AF study of patients with non-valvular atrial fibrillation (NVAF). The aim of this study was to characterize the Iberian edoxaban-treated cohort of ETNA-AF at baseline and to compare it with previously retrieved Portuguese data. Methods: Patients with NVAF treated with edoxaban and followed in Portuguese and Spanish centers were consecutively enrolled between June 2017 and January 2018. Only patients with a previous clinical decision to receive edoxaban were included. Patients’ baseline demographic and clinical parameters, medical history, and AF-related characteristics were retrieved. Results: A total of 892 NVAF patients, with a mean age of 73.9 years, were included, 75.3% of whom received high-dose (60 mg) and 24.7% low-dose (30 mg) edoxaban. Most patients (55.9%) were male. Of the patients receiving 30 mg and 60 mg edoxaban, 55.9% and 37.9%, respectively, had an estimated CHA2DS2-VASc score ≥4. Previous bleeding event rates were low, with a predominance of clinically relevant non-major bleeding (1.9%). Most patients (47.5%) with NVAF had paroxysmal AF, followed by 26.4% with permanent AF. Median overall CHA2DS2-VASc score was 3.0 and median HAS-BLED score was 2.0. Previous treatments mostly included vitamin K antagonists (35.7%). A considerably higher proportion of patients on low-dose edoxaban required dose adjustments (71.4% vs. 8.6%). Overall adherence to label dosing recommendations was 86.5%. Conclusions: This study provides valuable data on disease and patient profiles and will provide valuable insights into disease management and progression, as well as the safety, effectiveness, and patterns of cardiovascular events associated with edoxaban. Resumo: Introdução e objetivos: A fibrilhação auricular (FA) é a arritmia mais comum globalmente e associa-se a um substancial ónus de saúde. O novo anticoagulante oral (NOAC) edoxabano está a ser investigado no estudo europeu de vida real ETNA-AF em doentes com fibrilhação auricular não valvular (FANV). O objetivo deste estudo é caracterizar a coorte ibérica do ETNA-AF na base de dados e compará-la com dados portugueses prévios. Métodos: Doentes com FANV tratados com edoxabano e seguidos em centros portugueses e espanhóis foram consecutivamente incluídos no estudo entre junho de 2017 e janeiro de 2018. Apenas doentes com indicação prévia para receber edoxabano foram incluídos e os seus dados clínicos e demográficos, história clínica e características relacionadas com a FA foram registados. Resultados: Fora, incluídos 892 doentes com FANV, com média de 73,9 anos, 75,3% dos quais receberam a dose elevada (60 mg) e 24,7% a dose reduzida (30 mg) de edoxabano. A maioria dos doentes (55,9%) era do sexo masculino. Dos doentes que receberam 30 mg e 60 mg de edoxabano, 55,9% e 37,9%, respetivamente, tinham CHA2DS2-VASc estimado ≥ 4. As taxas de eventos hemorrágicos prévios foram baixas, com predominância de hemorragia não major clinicamente relevante (1,9%). A maioria (47,5%) dos doentes com FANV tinha FA paroxística, seguidos de 26,4% com FA permanente. A mediana de CHA2DS2-VASc global foi 3,0 e a mediana de HAS-BLED, 2,0. Os tratamentos prévios incluíram sobretudo VKAs (35,7%). Uma proporção consideravelmente maior de doentes a receber dose reduzida de edoxabano necessitou de ajustes de dose (71,4% versus 8,6%). A adesão global às recomendações de dose foi de 86,5%. Conclusões: Este estudo fornece dados importantes sobre a doença e o perfil dos doentes e possibilitará considerações futuras acerca da gestão e progressão da doença, bem como de segurança, efetividade e padrões de eventos cardiovasculares associados a edoxabano. Fibrilhação auricular Edoxabano Baseline Vida real Diseases of the circulatory (Cardiovascular) system In Revista Portuguesa de Cardiologia Elsevier, 2020 39(2020), 11, Seite 651-662 (DE-627)642886164 (DE-600)2586869-X 21742030 nnns volume:39 year:2020 number:11 pages:651-662 https://doi.org/10.1016/j.repc.2020.09.003 kostenfrei https://doaj.org/article/6a1eeab3a2fa490c9eaf0ab85f29cf75 kostenfrei http://www.sciencedirect.com/science/article/pii/S0870255120304066 kostenfrei https://doaj.org/toc/0870-2551 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 39 2020 11 651-662
allfieldsGer	10.1016/j.repc.2020.09.003 doi (DE-627)DOAJ044087381 (DE-599)DOAJ6a1eeab3a2fa490c9eaf0ab85f29cf75 DE-627 ger DE-627 rakwb eng por RC666-701 Pedro Monteiro verfasserin aut Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction and Objectives: Atrial fibrillation (AF) is the most common form of arrhythmia worldwide and a significant health burden. Edoxaban, a recent novel oral anticoagulant (NOAC), is being investigated in the European real-world ETNA-AF study of patients with non-valvular atrial fibrillation (NVAF). The aim of this study was to characterize the Iberian edoxaban-treated cohort of ETNA-AF at baseline and to compare it with previously retrieved Portuguese data. Methods: Patients with NVAF treated with edoxaban and followed in Portuguese and Spanish centers were consecutively enrolled between June 2017 and January 2018. Only patients with a previous clinical decision to receive edoxaban were included. Patients’ baseline demographic and clinical parameters, medical history, and AF-related characteristics were retrieved. Results: A total of 892 NVAF patients, with a mean age of 73.9 years, were included, 75.3% of whom received high-dose (60 mg) and 24.7% low-dose (30 mg) edoxaban. Most patients (55.9%) were male. Of the patients receiving 30 mg and 60 mg edoxaban, 55.9% and 37.9%, respectively, had an estimated CHA2DS2-VASc score ≥4. Previous bleeding event rates were low, with a predominance of clinically relevant non-major bleeding (1.9%). Most patients (47.5%) with NVAF had paroxysmal AF, followed by 26.4% with permanent AF. Median overall CHA2DS2-VASc score was 3.0 and median HAS-BLED score was 2.0. Previous treatments mostly included vitamin K antagonists (35.7%). A considerably higher proportion of patients on low-dose edoxaban required dose adjustments (71.4% vs. 8.6%). Overall adherence to label dosing recommendations was 86.5%. Conclusions: This study provides valuable data on disease and patient profiles and will provide valuable insights into disease management and progression, as well as the safety, effectiveness, and patterns of cardiovascular events associated with edoxaban. Resumo: Introdução e objetivos: A fibrilhação auricular (FA) é a arritmia mais comum globalmente e associa-se a um substancial ónus de saúde. O novo anticoagulante oral (NOAC) edoxabano está a ser investigado no estudo europeu de vida real ETNA-AF em doentes com fibrilhação auricular não valvular (FANV). O objetivo deste estudo é caracterizar a coorte ibérica do ETNA-AF na base de dados e compará-la com dados portugueses prévios. Métodos: Doentes com FANV tratados com edoxabano e seguidos em centros portugueses e espanhóis foram consecutivamente incluídos no estudo entre junho de 2017 e janeiro de 2018. Apenas doentes com indicação prévia para receber edoxabano foram incluídos e os seus dados clínicos e demográficos, história clínica e características relacionadas com a FA foram registados. Resultados: Fora, incluídos 892 doentes com FANV, com média de 73,9 anos, 75,3% dos quais receberam a dose elevada (60 mg) e 24,7% a dose reduzida (30 mg) de edoxabano. A maioria dos doentes (55,9%) era do sexo masculino. Dos doentes que receberam 30 mg e 60 mg de edoxabano, 55,9% e 37,9%, respetivamente, tinham CHA2DS2-VASc estimado ≥ 4. As taxas de eventos hemorrágicos prévios foram baixas, com predominância de hemorragia não major clinicamente relevante (1,9%). A maioria (47,5%) dos doentes com FANV tinha FA paroxística, seguidos de 26,4% com FA permanente. A mediana de CHA2DS2-VASc global foi 3,0 e a mediana de HAS-BLED, 2,0. Os tratamentos prévios incluíram sobretudo VKAs (35,7%). Uma proporção consideravelmente maior de doentes a receber dose reduzida de edoxabano necessitou de ajustes de dose (71,4% versus 8,6%). A adesão global às recomendações de dose foi de 86,5%. Conclusões: Este estudo fornece dados importantes sobre a doença e o perfil dos doentes e possibilitará considerações futuras acerca da gestão e progressão da doença, bem como de segurança, efetividade e padrões de eventos cardiovasculares associados a edoxabano. Fibrilhação auricular Edoxabano Baseline Vida real Diseases of the circulatory (Cardiovascular) system In Revista Portuguesa de Cardiologia Elsevier, 2020 39(2020), 11, Seite 651-662 (DE-627)642886164 (DE-600)2586869-X 21742030 nnns volume:39 year:2020 number:11 pages:651-662 https://doi.org/10.1016/j.repc.2020.09.003 kostenfrei https://doaj.org/article/6a1eeab3a2fa490c9eaf0ab85f29cf75 kostenfrei http://www.sciencedirect.com/science/article/pii/S0870255120304066 kostenfrei https://doaj.org/toc/0870-2551 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 39 2020 11 651-662
allfieldsSound	10.1016/j.repc.2020.09.003 doi (DE-627)DOAJ044087381 (DE-599)DOAJ6a1eeab3a2fa490c9eaf0ab85f29cf75 DE-627 ger DE-627 rakwb eng por RC666-701 Pedro Monteiro verfasserin aut Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction and Objectives: Atrial fibrillation (AF) is the most common form of arrhythmia worldwide and a significant health burden. Edoxaban, a recent novel oral anticoagulant (NOAC), is being investigated in the European real-world ETNA-AF study of patients with non-valvular atrial fibrillation (NVAF). The aim of this study was to characterize the Iberian edoxaban-treated cohort of ETNA-AF at baseline and to compare it with previously retrieved Portuguese data. Methods: Patients with NVAF treated with edoxaban and followed in Portuguese and Spanish centers were consecutively enrolled between June 2017 and January 2018. Only patients with a previous clinical decision to receive edoxaban were included. Patients’ baseline demographic and clinical parameters, medical history, and AF-related characteristics were retrieved. Results: A total of 892 NVAF patients, with a mean age of 73.9 years, were included, 75.3% of whom received high-dose (60 mg) and 24.7% low-dose (30 mg) edoxaban. Most patients (55.9%) were male. Of the patients receiving 30 mg and 60 mg edoxaban, 55.9% and 37.9%, respectively, had an estimated CHA2DS2-VASc score ≥4. Previous bleeding event rates were low, with a predominance of clinically relevant non-major bleeding (1.9%). Most patients (47.5%) with NVAF had paroxysmal AF, followed by 26.4% with permanent AF. Median overall CHA2DS2-VASc score was 3.0 and median HAS-BLED score was 2.0. Previous treatments mostly included vitamin K antagonists (35.7%). A considerably higher proportion of patients on low-dose edoxaban required dose adjustments (71.4% vs. 8.6%). Overall adherence to label dosing recommendations was 86.5%. Conclusions: This study provides valuable data on disease and patient profiles and will provide valuable insights into disease management and progression, as well as the safety, effectiveness, and patterns of cardiovascular events associated with edoxaban. Resumo: Introdução e objetivos: A fibrilhação auricular (FA) é a arritmia mais comum globalmente e associa-se a um substancial ónus de saúde. O novo anticoagulante oral (NOAC) edoxabano está a ser investigado no estudo europeu de vida real ETNA-AF em doentes com fibrilhação auricular não valvular (FANV). O objetivo deste estudo é caracterizar a coorte ibérica do ETNA-AF na base de dados e compará-la com dados portugueses prévios. Métodos: Doentes com FANV tratados com edoxabano e seguidos em centros portugueses e espanhóis foram consecutivamente incluídos no estudo entre junho de 2017 e janeiro de 2018. Apenas doentes com indicação prévia para receber edoxabano foram incluídos e os seus dados clínicos e demográficos, história clínica e características relacionadas com a FA foram registados. Resultados: Fora, incluídos 892 doentes com FANV, com média de 73,9 anos, 75,3% dos quais receberam a dose elevada (60 mg) e 24,7% a dose reduzida (30 mg) de edoxabano. A maioria dos doentes (55,9%) era do sexo masculino. Dos doentes que receberam 30 mg e 60 mg de edoxabano, 55,9% e 37,9%, respetivamente, tinham CHA2DS2-VASc estimado ≥ 4. As taxas de eventos hemorrágicos prévios foram baixas, com predominância de hemorragia não major clinicamente relevante (1,9%). A maioria (47,5%) dos doentes com FANV tinha FA paroxística, seguidos de 26,4% com FA permanente. A mediana de CHA2DS2-VASc global foi 3,0 e a mediana de HAS-BLED, 2,0. Os tratamentos prévios incluíram sobretudo VKAs (35,7%). Uma proporção consideravelmente maior de doentes a receber dose reduzida de edoxabano necessitou de ajustes de dose (71,4% versus 8,6%). A adesão global às recomendações de dose foi de 86,5%. Conclusões: Este estudo fornece dados importantes sobre a doença e o perfil dos doentes e possibilitará considerações futuras acerca da gestão e progressão da doença, bem como de segurança, efetividade e padrões de eventos cardiovasculares associados a edoxabano. Fibrilhação auricular Edoxabano Baseline Vida real Diseases of the circulatory (Cardiovascular) system In Revista Portuguesa de Cardiologia Elsevier, 2020 39(2020), 11, Seite 651-662 (DE-627)642886164 (DE-600)2586869-X 21742030 nnns volume:39 year:2020 number:11 pages:651-662 https://doi.org/10.1016/j.repc.2020.09.003 kostenfrei https://doaj.org/article/6a1eeab3a2fa490c9eaf0ab85f29cf75 kostenfrei http://www.sciencedirect.com/science/article/pii/S0870255120304066 kostenfrei https://doaj.org/toc/0870-2551 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 39 2020 11 651-662
language	English Portuguese
source	In Revista Portuguesa de Cardiologia 39(2020), 11, Seite 651-662 volume:39 year:2020 number:11 pages:651-662
sourceStr	In Revista Portuguesa de Cardiologia 39(2020), 11, Seite 651-662 volume:39 year:2020 number:11 pages:651-662
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Fibrilhação auricular Edoxabano Baseline Vida real Diseases of the circulatory (Cardiovascular) system
isfreeaccess_bool	true
container_title	Revista Portuguesa de Cardiologia
authorswithroles_txt_mv	Pedro Monteiro @@aut@@
publishDateDaySort_date	2020-01-01T00:00:00Z
hierarchy_top_id	642886164
id	DOAJ044087381
language_de	englisch portugiesisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ044087381</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501190657.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.repc.2020.09.003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ044087381</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ6a1eeab3a2fa490c9eaf0ab85f29cf75</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">por</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Pedro Monteiro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction and Objectives: Atrial fibrillation (AF) is the most common form of arrhythmia worldwide and a significant health burden. Edoxaban, a recent novel oral anticoagulant (NOAC), is being investigated in the European real-world ETNA-AF study of patients with non-valvular atrial fibrillation (NVAF). The aim of this study was to characterize the Iberian edoxaban-treated cohort of ETNA-AF at baseline and to compare it with previously retrieved Portuguese data. Methods: Patients with NVAF treated with edoxaban and followed in Portuguese and Spanish centers were consecutively enrolled between June 2017 and January 2018. Only patients with a previous clinical decision to receive edoxaban were included. Patients’ baseline demographic and clinical parameters, medical history, and AF-related characteristics were retrieved. Results: A total of 892 NVAF patients, with a mean age of 73.9 years, were included, 75.3% of whom received high-dose (60 mg) and 24.7% low-dose (30 mg) edoxaban. Most patients (55.9%) were male. Of the patients receiving 30 mg and 60 mg edoxaban, 55.9% and 37.9%, respectively, had an estimated CHA2DS2-VASc score ≥4. Previous bleeding event rates were low, with a predominance of clinically relevant non-major bleeding (1.9%). Most patients (47.5%) with NVAF had paroxysmal AF, followed by 26.4% with permanent AF. Median overall CHA2DS2-VASc score was 3.0 and median HAS-BLED score was 2.0. Previous treatments mostly included vitamin K antagonists (35.7%). A considerably higher proportion of patients on low-dose edoxaban required dose adjustments (71.4% vs. 8.6%). Overall adherence to label dosing recommendations was 86.5%. Conclusions: This study provides valuable data on disease and patient profiles and will provide valuable insights into disease management and progression, as well as the safety, effectiveness, and patterns of cardiovascular events associated with edoxaban. Resumo: Introdução e objetivos: A fibrilhação auricular (FA) é a arritmia mais comum globalmente e associa-se a um substancial ónus de saúde. O novo anticoagulante oral (NOAC) edoxabano está a ser investigado no estudo europeu de vida real ETNA-AF em doentes com fibrilhação auricular não valvular (FANV). O objetivo deste estudo é caracterizar a coorte ibérica do ETNA-AF na base de dados e compará-la com dados portugueses prévios. Métodos: Doentes com FANV tratados com edoxabano e seguidos em centros portugueses e espanhóis foram consecutivamente incluídos no estudo entre junho de 2017 e janeiro de 2018. Apenas doentes com indicação prévia para receber edoxabano foram incluídos e os seus dados clínicos e demográficos, história clínica e características relacionadas com a FA foram registados. Resultados: Fora, incluídos 892 doentes com FANV, com média de 73,9 anos, 75,3% dos quais receberam a dose elevada (60 mg) e 24,7% a dose reduzida (30 mg) de edoxabano. A maioria dos doentes (55,9%) era do sexo masculino. Dos doentes que receberam 30 mg e 60 mg de edoxabano, 55,9% e 37,9%, respetivamente, tinham CHA2DS2-VASc estimado ≥ 4. As taxas de eventos hemorrágicos prévios foram baixas, com predominância de hemorragia não major clinicamente relevante (1,9%). A maioria (47,5%) dos doentes com FANV tinha FA paroxística, seguidos de 26,4% com FA permanente. A mediana de CHA2DS2-VASc global foi 3,0 e a mediana de HAS-BLED, 2,0. Os tratamentos prévios incluíram sobretudo VKAs (35,7%). Uma proporção consideravelmente maior de doentes a receber dose reduzida de edoxabano necessitou de ajustes de dose (71,4% versus 8,6%). A adesão global às recomendações de dose foi de 86,5%. Conclusões: Este estudo fornece dados importantes sobre a doença e o perfil dos doentes e possibilitará considerações futuras acerca da gestão e progressão da doença, bem como de segurança, efetividade e padrões de eventos cardiovasculares associados a edoxabano.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fibrilhação auricular</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Edoxabano</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Baseline</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Vida real</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Revista Portuguesa de Cardiologia</subfield><subfield code="d">Elsevier, 2020</subfield><subfield code="g">39(2020), 11, Seite 651-662</subfield><subfield code="w">(DE-627)642886164</subfield><subfield code="w">(DE-600)2586869-X</subfield><subfield code="x">21742030</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:39</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:651-662</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.repc.2020.09.003</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/6a1eeab3a2fa490c9eaf0ab85f29cf75</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S0870255120304066</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0870-2551</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">39</subfield><subfield code="j">2020</subfield><subfield code="e">11</subfield><subfield code="h">651-662</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Pedro Monteiro
spellingShingle	Pedro Monteiro misc RC666-701 misc Fibrilhação auricular misc Edoxabano misc Baseline misc Vida real misc Diseases of the circulatory (Cardiovascular) system Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data
authorStr	Pedro Monteiro
ppnlink_with_tag_str_mv	@@773@@(DE-627)642886164
format	electronic Article
delete_txt_mv	keep
author_role	aut
collection	DOAJ
remote_str	true
callnumber-label	RC666-701
illustrated	Not Illustrated
issn	21742030
topic_title	RC666-701 Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data Fibrilhação auricular Edoxabano Baseline Vida real
topic	misc RC666-701 misc Fibrilhação auricular misc Edoxabano misc Baseline misc Vida real misc Diseases of the circulatory (Cardiovascular) system
topic_unstemmed	misc RC666-701 misc Fibrilhação auricular misc Edoxabano misc Baseline misc Vida real misc Diseases of the circulatory (Cardiovascular) system
topic_browse	misc RC666-701 misc Fibrilhação auricular misc Edoxabano misc Baseline misc Vida real misc Diseases of the circulatory (Cardiovascular) system
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Revista Portuguesa de Cardiologia
hierarchy_parent_id	642886164
hierarchy_top_title	Revista Portuguesa de Cardiologia
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)642886164 (DE-600)2586869-X
title	Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data
ctrlnum	(DE-627)DOAJ044087381 (DE-599)DOAJ6a1eeab3a2fa490c9eaf0ab85f29cf75
title_full	Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data
author_sort	Pedro Monteiro
journal	Revista Portuguesa de Cardiologia
journalStr	Revista Portuguesa de Cardiologia
callnumber-first-code	R
lang_code	eng por
isOA_bool	true
recordtype	marc
publishDateSort	2020
contenttype_str_mv	txt
container_start_page	651
author_browse	Pedro Monteiro
container_volume	39
class	RC666-701
format_se	Elektronische Aufsätze
author-letter	Pedro Monteiro
doi_str_mv	10.1016/j.repc.2020.09.003
title_sort	edoxaban treatment in routine clinical practice in patients with non-valvular atrial fibrillation (etna-af) in iberia: baseline data
callnumber	RC666-701
title_auth	Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data
abstract	Introduction and Objectives: Atrial fibrillation (AF) is the most common form of arrhythmia worldwide and a significant health burden. Edoxaban, a recent novel oral anticoagulant (NOAC), is being investigated in the European real-world ETNA-AF study of patients with non-valvular atrial fibrillation (NVAF). The aim of this study was to characterize the Iberian edoxaban-treated cohort of ETNA-AF at baseline and to compare it with previously retrieved Portuguese data. Methods: Patients with NVAF treated with edoxaban and followed in Portuguese and Spanish centers were consecutively enrolled between June 2017 and January 2018. Only patients with a previous clinical decision to receive edoxaban were included. Patients’ baseline demographic and clinical parameters, medical history, and AF-related characteristics were retrieved. Results: A total of 892 NVAF patients, with a mean age of 73.9 years, were included, 75.3% of whom received high-dose (60 mg) and 24.7% low-dose (30 mg) edoxaban. Most patients (55.9%) were male. Of the patients receiving 30 mg and 60 mg edoxaban, 55.9% and 37.9%, respectively, had an estimated CHA2DS2-VASc score ≥4. Previous bleeding event rates were low, with a predominance of clinically relevant non-major bleeding (1.9%). Most patients (47.5%) with NVAF had paroxysmal AF, followed by 26.4% with permanent AF. Median overall CHA2DS2-VASc score was 3.0 and median HAS-BLED score was 2.0. Previous treatments mostly included vitamin K antagonists (35.7%). A considerably higher proportion of patients on low-dose edoxaban required dose adjustments (71.4% vs. 8.6%). Overall adherence to label dosing recommendations was 86.5%. Conclusions: This study provides valuable data on disease and patient profiles and will provide valuable insights into disease management and progression, as well as the safety, effectiveness, and patterns of cardiovascular events associated with edoxaban. Resumo: Introdução e objetivos: A fibrilhação auricular (FA) é a arritmia mais comum globalmente e associa-se a um substancial ónus de saúde. O novo anticoagulante oral (NOAC) edoxabano está a ser investigado no estudo europeu de vida real ETNA-AF em doentes com fibrilhação auricular não valvular (FANV). O objetivo deste estudo é caracterizar a coorte ibérica do ETNA-AF na base de dados e compará-la com dados portugueses prévios. Métodos: Doentes com FANV tratados com edoxabano e seguidos em centros portugueses e espanhóis foram consecutivamente incluídos no estudo entre junho de 2017 e janeiro de 2018. Apenas doentes com indicação prévia para receber edoxabano foram incluídos e os seus dados clínicos e demográficos, história clínica e características relacionadas com a FA foram registados. Resultados: Fora, incluídos 892 doentes com FANV, com média de 73,9 anos, 75,3% dos quais receberam a dose elevada (60 mg) e 24,7% a dose reduzida (30 mg) de edoxabano. A maioria dos doentes (55,9%) era do sexo masculino. Dos doentes que receberam 30 mg e 60 mg de edoxabano, 55,9% e 37,9%, respetivamente, tinham CHA2DS2-VASc estimado ≥ 4. As taxas de eventos hemorrágicos prévios foram baixas, com predominância de hemorragia não major clinicamente relevante (1,9%). A maioria (47,5%) dos doentes com FANV tinha FA paroxística, seguidos de 26,4% com FA permanente. A mediana de CHA2DS2-VASc global foi 3,0 e a mediana de HAS-BLED, 2,0. Os tratamentos prévios incluíram sobretudo VKAs (35,7%). Uma proporção consideravelmente maior de doentes a receber dose reduzida de edoxabano necessitou de ajustes de dose (71,4% versus 8,6%). A adesão global às recomendações de dose foi de 86,5%. Conclusões: Este estudo fornece dados importantes sobre a doença e o perfil dos doentes e possibilitará considerações futuras acerca da gestão e progressão da doença, bem como de segurança, efetividade e padrões de eventos cardiovasculares associados a edoxabano.
abstractGer	Introduction and Objectives: Atrial fibrillation (AF) is the most common form of arrhythmia worldwide and a significant health burden. Edoxaban, a recent novel oral anticoagulant (NOAC), is being investigated in the European real-world ETNA-AF study of patients with non-valvular atrial fibrillation (NVAF). The aim of this study was to characterize the Iberian edoxaban-treated cohort of ETNA-AF at baseline and to compare it with previously retrieved Portuguese data. Methods: Patients with NVAF treated with edoxaban and followed in Portuguese and Spanish centers were consecutively enrolled between June 2017 and January 2018. Only patients with a previous clinical decision to receive edoxaban were included. Patients’ baseline demographic and clinical parameters, medical history, and AF-related characteristics were retrieved. Results: A total of 892 NVAF patients, with a mean age of 73.9 years, were included, 75.3% of whom received high-dose (60 mg) and 24.7% low-dose (30 mg) edoxaban. Most patients (55.9%) were male. Of the patients receiving 30 mg and 60 mg edoxaban, 55.9% and 37.9%, respectively, had an estimated CHA2DS2-VASc score ≥4. Previous bleeding event rates were low, with a predominance of clinically relevant non-major bleeding (1.9%). Most patients (47.5%) with NVAF had paroxysmal AF, followed by 26.4% with permanent AF. Median overall CHA2DS2-VASc score was 3.0 and median HAS-BLED score was 2.0. Previous treatments mostly included vitamin K antagonists (35.7%). A considerably higher proportion of patients on low-dose edoxaban required dose adjustments (71.4% vs. 8.6%). Overall adherence to label dosing recommendations was 86.5%. Conclusions: This study provides valuable data on disease and patient profiles and will provide valuable insights into disease management and progression, as well as the safety, effectiveness, and patterns of cardiovascular events associated with edoxaban. Resumo: Introdução e objetivos: A fibrilhação auricular (FA) é a arritmia mais comum globalmente e associa-se a um substancial ónus de saúde. O novo anticoagulante oral (NOAC) edoxabano está a ser investigado no estudo europeu de vida real ETNA-AF em doentes com fibrilhação auricular não valvular (FANV). O objetivo deste estudo é caracterizar a coorte ibérica do ETNA-AF na base de dados e compará-la com dados portugueses prévios. Métodos: Doentes com FANV tratados com edoxabano e seguidos em centros portugueses e espanhóis foram consecutivamente incluídos no estudo entre junho de 2017 e janeiro de 2018. Apenas doentes com indicação prévia para receber edoxabano foram incluídos e os seus dados clínicos e demográficos, história clínica e características relacionadas com a FA foram registados. Resultados: Fora, incluídos 892 doentes com FANV, com média de 73,9 anos, 75,3% dos quais receberam a dose elevada (60 mg) e 24,7% a dose reduzida (30 mg) de edoxabano. A maioria dos doentes (55,9%) era do sexo masculino. Dos doentes que receberam 30 mg e 60 mg de edoxabano, 55,9% e 37,9%, respetivamente, tinham CHA2DS2-VASc estimado ≥ 4. As taxas de eventos hemorrágicos prévios foram baixas, com predominância de hemorragia não major clinicamente relevante (1,9%). A maioria (47,5%) dos doentes com FANV tinha FA paroxística, seguidos de 26,4% com FA permanente. A mediana de CHA2DS2-VASc global foi 3,0 e a mediana de HAS-BLED, 2,0. Os tratamentos prévios incluíram sobretudo VKAs (35,7%). Uma proporção consideravelmente maior de doentes a receber dose reduzida de edoxabano necessitou de ajustes de dose (71,4% versus 8,6%). A adesão global às recomendações de dose foi de 86,5%. Conclusões: Este estudo fornece dados importantes sobre a doença e o perfil dos doentes e possibilitará considerações futuras acerca da gestão e progressão da doença, bem como de segurança, efetividade e padrões de eventos cardiovasculares associados a edoxabano.
abstract_unstemmed	Introduction and Objectives: Atrial fibrillation (AF) is the most common form of arrhythmia worldwide and a significant health burden. Edoxaban, a recent novel oral anticoagulant (NOAC), is being investigated in the European real-world ETNA-AF study of patients with non-valvular atrial fibrillation (NVAF). The aim of this study was to characterize the Iberian edoxaban-treated cohort of ETNA-AF at baseline and to compare it with previously retrieved Portuguese data. Methods: Patients with NVAF treated with edoxaban and followed in Portuguese and Spanish centers were consecutively enrolled between June 2017 and January 2018. Only patients with a previous clinical decision to receive edoxaban were included. Patients’ baseline demographic and clinical parameters, medical history, and AF-related characteristics were retrieved. Results: A total of 892 NVAF patients, with a mean age of 73.9 years, were included, 75.3% of whom received high-dose (60 mg) and 24.7% low-dose (30 mg) edoxaban. Most patients (55.9%) were male. Of the patients receiving 30 mg and 60 mg edoxaban, 55.9% and 37.9%, respectively, had an estimated CHA2DS2-VASc score ≥4. Previous bleeding event rates were low, with a predominance of clinically relevant non-major bleeding (1.9%). Most patients (47.5%) with NVAF had paroxysmal AF, followed by 26.4% with permanent AF. Median overall CHA2DS2-VASc score was 3.0 and median HAS-BLED score was 2.0. Previous treatments mostly included vitamin K antagonists (35.7%). A considerably higher proportion of patients on low-dose edoxaban required dose adjustments (71.4% vs. 8.6%). Overall adherence to label dosing recommendations was 86.5%. Conclusions: This study provides valuable data on disease and patient profiles and will provide valuable insights into disease management and progression, as well as the safety, effectiveness, and patterns of cardiovascular events associated with edoxaban. Resumo: Introdução e objetivos: A fibrilhação auricular (FA) é a arritmia mais comum globalmente e associa-se a um substancial ónus de saúde. O novo anticoagulante oral (NOAC) edoxabano está a ser investigado no estudo europeu de vida real ETNA-AF em doentes com fibrilhação auricular não valvular (FANV). O objetivo deste estudo é caracterizar a coorte ibérica do ETNA-AF na base de dados e compará-la com dados portugueses prévios. Métodos: Doentes com FANV tratados com edoxabano e seguidos em centros portugueses e espanhóis foram consecutivamente incluídos no estudo entre junho de 2017 e janeiro de 2018. Apenas doentes com indicação prévia para receber edoxabano foram incluídos e os seus dados clínicos e demográficos, história clínica e características relacionadas com a FA foram registados. Resultados: Fora, incluídos 892 doentes com FANV, com média de 73,9 anos, 75,3% dos quais receberam a dose elevada (60 mg) e 24,7% a dose reduzida (30 mg) de edoxabano. A maioria dos doentes (55,9%) era do sexo masculino. Dos doentes que receberam 30 mg e 60 mg de edoxabano, 55,9% e 37,9%, respetivamente, tinham CHA2DS2-VASc estimado ≥ 4. As taxas de eventos hemorrágicos prévios foram baixas, com predominância de hemorragia não major clinicamente relevante (1,9%). A maioria (47,5%) dos doentes com FANV tinha FA paroxística, seguidos de 26,4% com FA permanente. A mediana de CHA2DS2-VASc global foi 3,0 e a mediana de HAS-BLED, 2,0. Os tratamentos prévios incluíram sobretudo VKAs (35,7%). Uma proporção consideravelmente maior de doentes a receber dose reduzida de edoxabano necessitou de ajustes de dose (71,4% versus 8,6%). A adesão global às recomendações de dose foi de 86,5%. Conclusões: Este estudo fornece dados importantes sobre a doença e o perfil dos doentes e possibilitará considerações futuras acerca da gestão e progressão da doença, bem como de segurança, efetividade e padrões de eventos cardiovasculares associados a edoxabano.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	11
title_short	Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data
url	https://doi.org/10.1016/j.repc.2020.09.003 https://doaj.org/article/6a1eeab3a2fa490c9eaf0ab85f29cf75 http://www.sciencedirect.com/science/article/pii/S0870255120304066 https://doaj.org/toc/0870-2551
remote_bool	true
ppnlink	642886164
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1016/j.repc.2020.09.003
callnumber-a	RC666-701
up_date	2024-07-03T21:09:06.958Z
_version_	1803593656011063296
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ044087381</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501190657.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.repc.2020.09.003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ044087381</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ6a1eeab3a2fa490c9eaf0ab85f29cf75</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">por</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Pedro Monteiro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction and Objectives: Atrial fibrillation (AF) is the most common form of arrhythmia worldwide and a significant health burden. Edoxaban, a recent novel oral anticoagulant (NOAC), is being investigated in the European real-world ETNA-AF study of patients with non-valvular atrial fibrillation (NVAF). The aim of this study was to characterize the Iberian edoxaban-treated cohort of ETNA-AF at baseline and to compare it with previously retrieved Portuguese data. Methods: Patients with NVAF treated with edoxaban and followed in Portuguese and Spanish centers were consecutively enrolled between June 2017 and January 2018. Only patients with a previous clinical decision to receive edoxaban were included. Patients’ baseline demographic and clinical parameters, medical history, and AF-related characteristics were retrieved. Results: A total of 892 NVAF patients, with a mean age of 73.9 years, were included, 75.3% of whom received high-dose (60 mg) and 24.7% low-dose (30 mg) edoxaban. Most patients (55.9%) were male. Of the patients receiving 30 mg and 60 mg edoxaban, 55.9% and 37.9%, respectively, had an estimated CHA2DS2-VASc score ≥4. Previous bleeding event rates were low, with a predominance of clinically relevant non-major bleeding (1.9%). Most patients (47.5%) with NVAF had paroxysmal AF, followed by 26.4% with permanent AF. Median overall CHA2DS2-VASc score was 3.0 and median HAS-BLED score was 2.0. Previous treatments mostly included vitamin K antagonists (35.7%). A considerably higher proportion of patients on low-dose edoxaban required dose adjustments (71.4% vs. 8.6%). Overall adherence to label dosing recommendations was 86.5%. Conclusions: This study provides valuable data on disease and patient profiles and will provide valuable insights into disease management and progression, as well as the safety, effectiveness, and patterns of cardiovascular events associated with edoxaban. Resumo: Introdução e objetivos: A fibrilhação auricular (FA) é a arritmia mais comum globalmente e associa-se a um substancial ónus de saúde. O novo anticoagulante oral (NOAC) edoxabano está a ser investigado no estudo europeu de vida real ETNA-AF em doentes com fibrilhação auricular não valvular (FANV). O objetivo deste estudo é caracterizar a coorte ibérica do ETNA-AF na base de dados e compará-la com dados portugueses prévios. Métodos: Doentes com FANV tratados com edoxabano e seguidos em centros portugueses e espanhóis foram consecutivamente incluídos no estudo entre junho de 2017 e janeiro de 2018. Apenas doentes com indicação prévia para receber edoxabano foram incluídos e os seus dados clínicos e demográficos, história clínica e características relacionadas com a FA foram registados. Resultados: Fora, incluídos 892 doentes com FANV, com média de 73,9 anos, 75,3% dos quais receberam a dose elevada (60 mg) e 24,7% a dose reduzida (30 mg) de edoxabano. A maioria dos doentes (55,9%) era do sexo masculino. Dos doentes que receberam 30 mg e 60 mg de edoxabano, 55,9% e 37,9%, respetivamente, tinham CHA2DS2-VASc estimado ≥ 4. As taxas de eventos hemorrágicos prévios foram baixas, com predominância de hemorragia não major clinicamente relevante (1,9%). A maioria (47,5%) dos doentes com FANV tinha FA paroxística, seguidos de 26,4% com FA permanente. A mediana de CHA2DS2-VASc global foi 3,0 e a mediana de HAS-BLED, 2,0. Os tratamentos prévios incluíram sobretudo VKAs (35,7%). Uma proporção consideravelmente maior de doentes a receber dose reduzida de edoxabano necessitou de ajustes de dose (71,4% versus 8,6%). A adesão global às recomendações de dose foi de 86,5%. Conclusões: Este estudo fornece dados importantes sobre a doença e o perfil dos doentes e possibilitará considerações futuras acerca da gestão e progressão da doença, bem como de segurança, efetividade e padrões de eventos cardiovasculares associados a edoxabano.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fibrilhação auricular</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Edoxabano</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Baseline</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Vida real</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Revista Portuguesa de Cardiologia</subfield><subfield code="d">Elsevier, 2020</subfield><subfield code="g">39(2020), 11, Seite 651-662</subfield><subfield code="w">(DE-627)642886164</subfield><subfield code="w">(DE-600)2586869-X</subfield><subfield code="x">21742030</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:39</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:651-662</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.repc.2020.09.003</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/6a1eeab3a2fa490c9eaf0ab85f29cf75</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S0870255120304066</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0870-2551</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">39</subfield><subfield code="j">2020</subfield><subfield code="e">11</subfield><subfield code="h">651-662</subfield></datafield></record></collection>
score	7.4006615

Nicht das Richtige dabei?

Schreiben Sie uns!

Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?